Clinical Trials
Below are current clinical trials.
273 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
-
Rochester, Minn.
Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics). In this approach, we isolate and affinity-column immobilize the IgG fraction from patient serum before and after immune therapy for melanoma, and expose the immobilized antibodies to bacteriophage expressing approximately 2x109 overlapping cDNA sequences of paired (same patient derived plasma and cancer cells) melanoma genomic RNA. Phage, expressing melanoma cDNA express the proteins/peptides on their capsid are “recognized” by the immobilized antibodies are retained in the column, and subsequently eluted for DNA sequencing. Comparison of the DNA profiles of the eluted phage using pre-immunotherapy and post-immunotherapy patient sera will reveal emergence of new antibodies (post-immunotherapy gain of antibodies) against proteins of potential interest for melanoma targeting. In the current proposal, we hypothesize that reacting COVID serum from patients that have recovered from COVID infection and compare to non-infected self-serum (if available) and control healthy volunteer serum (available in our lab) may identify protein targets that have developed as a result of the COVID infection and could be useful in the development of a COVID vaccine as well as a serologic test for anti-COVID immunity.
-
Eau Claire, Wis., Rochester, Minn.
The primary objective of Aim 1 of this study are to identify personal and social determinant of health-related key factors that present as a barriers to use of non-emergent telehealth care during the COVID-19 pandemic. Aim 1 will use a qualitative study design to understand the experiences of patients along with social determinants of health (SDOH). The results of the qualitative work will be used by the research team to design the survey for administration in Aim 2.
The primary objectgive of Aim 2 of this study is to assess personal and social determinants of health that are associated with patient’s decision to prefer face-to-face visits compared with telehealth appointments for non-emergent care.
-
Rochester, Minn.
The purpose of this study is to characterize the mucosal microbiome in patients who have recently been treated for Clostridium-difficile Infection (CDI) in comparison to that of control population to determine the effect of the mucosal associated microbiome on outcome of CDI.
-
Jacksonville, Fla.
The purpose of this study is to accurately determine the negative predictive value of skin testing with antibiotics.
-
Rochester, Minn.
The main objective of this study is to identify minimally invasive, blood-based methylomic markers by comparing blood cfDNA methylation patterns among HIV-infected and uninfected HCC patients, and in HIV-infected but HCC-free patients.
-
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the patient-reported outcome (PRO) endpoints.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to utilize liver allografts from HCV seropositive donors into 10 HCV seronegative recipients.
-
Rochester, Minn.
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine whether adding clofazimine in a treatment regimen for patients with non-tuberculous mycobacterial (NTM) infections will improve low clinical success rates in NTM infections, its mode of action, and literature reported clinical data in both NTM and multidrug-resistant tuberculosis.